Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio ...

Hims & Hers (NASDAQ: HIMS) stock has done well since the company went public a few years ago. It has soared by over 193% in ...

5. Hims and Hers Hims and Hers have been go-to brands for a while—think hair loss, skincare, and all that good stuff. They’re now offering weight loss meds like semaglutide, which is great if you’re ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...

If you’re dealing with male pattern baldness, there’s a good chance you’ve heard of or use finasteride. You also may have ...

If you’re reading this because you’re losing your hair, you’re not alone — hair loss is a common issue affecting more than ...

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no ... In contrast, shares of competitor Hims & Hers Health (HIMS) are plummeting following this news. Market Domination hosts Madison ...